Since its inception, the Cancer Research Institute has invested hundreds of millions of dollars to support research conducted by more than 3,200 scientists and clinicians worldwide to understand the immune system and how it can be harnessed to conquer all cancers. This work has laid the foundation for nearly every major cancer immunotherapy breakthrough over the past half century.
Guided by an international panel of the world's leading immunologists and cancer immunologists, including Nobel laureates and members of the U.S. National Academy of Sciences, CRI provides essential funding to support every stage of discovery, from laboratory investigation to clinical trials of the most promising cancer immunotherapies for patients.
Application Deadline: April 1; October 1
The CRI Irvington Postdoctoral Fellowship Program furthers career development and supports laboratory research for promising young scientists working under the mentorship of leading immunologists.
LOI Deadline: November 1
The Clinic and Laboratory Integration Program (CLIP) grants provide catalytic support for the translation of basic laboratory discoveries into novel therapies that can be tested in patients.
Application Deadline: January 15
The Lloyd J. Old STAR Program provides grants of $1.25 million over 5 years to mid-career scientists. This long-term funding is not be tied to a specific research project, but rather aims to provide a degree of flexibility and freedom for investigators to explore out-of-the-box and disruptive avenues of research. Candidates selected for this award are expected to be future “stars” in the field of cancer immunology: Scientists Taking Risks.
LOI Deadline: November 15
The CRI Technology Impact Award provides seed funding of up to $200,000 to be used over 12-24 months to address the gap between technology development and clinical application of cancer immunotherapies.
CRI's Impact Grants support research projects and initiatives aimed at advancing defined scientific and technological goals and addressing major challenges that would otherwise limit progress in cancer immunotherapy research and drug development.